Arundic Acid

Arundic acid (ONO-2506) is an astrocyte-modulating agent, which delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis. Arundic acid also increases the expression level of EAAT1 by activating the Akt, ERK, and NF-κB signaling pathways, which has the potential to eliminate excess glutamate and inhibit excitotoxic brain damage or death. Arundic acid has the potential for stroke and Alzheimer’s disease research[1][2][3].

Product Specifications

CAS Number

[185517-21-9]

Product Name Alternative

ONO-2506; (R) -2-Propyloctanoic acid

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/arundic-acid.html

Purity

98.0

Solubility

DMSO : 150 mg/mL (ultrasonic)

Smiles

CCCCCC[C@H](C(O)=O)CCC

Molecular Formula

C11H22O2

Molecular Weight

186.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Tomoyuki Hasegawa, et al. Process Development of ONO-2506: A Therapeutic Agent for Stroke and Alzheimer's Disease. Org. Process Res. Dev.200372168-171.|[2]Kato H, et al. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTPneurotoxicity in mice. Brain Res. 2004 Dec 24;1030 (1) :66-73.|[3]Karki P, et al. Arundic Acid Increases Expression and Function of Astrocytic Glutamate Transporter EAAT1 Via the ERK, Akt, and NF-κB Pathways. Mol Neurobiol. 2018 Jun;55 (6) :5031-5046.